This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Elon Musk has a flare for the dramatic, shocking Wall Street (and others) the first week

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Early in the morning of April 24, 2018, I woke with a knot in my stomach because I knew

Most conventional small molecule drugs engage directly with the engine of a protein’s function, aiming to often turning off an enzymatic activity associated with a disease. These drugs bind and compete against the natural substrate of the protein at what

Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three biotech companies are emerging leaders in the cell and gene therapy space, broadly defined. They

This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around

Today, Zafgen announced my resignation from their Board of Directors after 12 years of service. It’s a bittersweet moment for me: having been there since the beginning, I’ve watched, and supported, the Zafgen story through all the ups and downs

The private biotech sector is awash in capital today: funding over the last few quarters has been record-breaking, up over 250% since 2013, as biotech CEOs have worked hard to strengthen their companies’ balance sheets.  But in the process of

This blog post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. It’s heresy to write this but it’s trains not bicycles that come to mind when describing our partnering

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. Disappointing results in Alzheimer’s clinical trials seem to be announced on an almost monthly, and sometimes weekly basis: Merck’s

This blog was co-written by Doug Kerr, Head of Preclinical Research & Clinical Development, and Geoff McDonough, CEO, both of GenerationBio, as part of the From The Trenches feature of LifeSciVC. Our industry stands at the beginning of the most

The flood of capital continues to pour into the private biotech ecosystem, marking the current climate as the most prolific period of investing into the sector of all time. The first three months of 2018 secured yet another “biggest quarter

This blog was written by Tariq Kassum, COO and Head of Corporate Development at Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Experience can be a tough teacher. Over the last two decades as a biotech